Energenesis Biomedical Co (TPE:6657) Total Assets: NT$948.98 Mil (As of Dec. 2025)


TPE:6657 Energenesis Biomedical Co Ltd TPE:6657
64 GF Score
Price NT$35.30
GF Value NT$51.42
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Energenesis Biomedical Co Total Assets?

Energenesis Biomedical Co TPE:6657 64 Total Assets is NT$948.98 Mil as of Dec. 2025. GuruFocus rates TPE:6657 with a GF Score™ of 64/100 and a GF Value™ of NT$51.42 (Possible Value Trap). The stock has 3 warning signs investors should review.

Energenesis Biomedical Co's Total Assets for the quarter that ended in Dec. 2025 was NT$948.98 Mil.

During the past 12 months, Energenesis Biomedical Co's average Total Assets Growth Rate was -4.10% per year. During the past 3 years, the average Total Assets Growth Rate was -8.80% per year. During the past 5 years, the average Total Assets Growth Rate was -8.20% per year. During the past 10 years, the average Total Assets Growth Rate was -0.20% per year.

During the past 11 years, Energenesis Biomedical Co's highest 3-Year average Total Assets Growth Rate was 38.60%. The lowest was -10.20%. And the median was -4.00%.

Total Assets is connected with ROA %. Energenesis Biomedical Co's annualized ROA % for the quarter that ended in Dec. 2025 was -26.17%. Total Assets is also linked to Revenue through Asset Turnover. Energenesis Biomedical Co's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Energenesis Biomedical Co  (TPE:6657) Total Assets Explanation

Total Assets is connected with ROA %.

Energenesis Biomedical Co's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-259.168/( (1031.8+948.982)/ 2 )
=-259.168/990.391
=-26.17 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Energenesis Biomedical Co's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=2.815/( (1031.8+948.982)/ 2 )
=2.815/990.391
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Energenesis Biomedical Co Total Assets Related Terms

Energenesis Biomedical Co Total Assets Historical Data

* Premium members only.

The historical data trend for Energenesis Biomedical Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Energenesis Biomedical Co Total Assets Chart

Energenesis Biomedical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 885.81 630.86 828.57 780.64 948.98

Energenesis Biomedical Co Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 780.64 1,124.13 1,065.04 1,031.80 948.98
TPE:6657
64GF Score
Energenesis Biomedical Co Ltd TPE:6657
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Energenesis Biomedical Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Energenesis Biomedical Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=896.273+52.709
=948.98

Energenesis Biomedical Co's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=896.273+52.709
=948.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of NT$948.98 Mil mean?
Energenesis Biomedical Co (TPE:6657) has a Total Assets of NT$948.98 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Energenesis Biomedical Co and its competitors.
Is Energenesis Biomedical Co's Total Assets too high?
Energenesis Biomedical Co's current Total Assets is NT$948.98 Mil. Overall, Energenesis Biomedical Co has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Total Assets compare to VRTX and REGN?
Energenesis Biomedical Co's Total Assets of NT$948.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Energenesis Biomedical Co and its competitors. Energenesis Biomedical Co's current Total Assets is NT$948.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.42, compared to a current price of NT$35.30 — trading 31.3% below its estimated fair value. The current Total Assets is NT$948.98 Mil. Energenesis Biomedical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Total Assets is NT$948.98 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?

Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued. The current stock price of NT$35.30 is trading 31.3% below its estimated GF Value™ of NT$51.42. GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.

Key valuation signals for TPE:6657:

  • Total Assets: NT$948.98 Mil
  • GF Value™: NT$51.42 vs. price of NT$35.30 (31.3% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Energenesis Biomedical Co Business Description

Address No. 21, Lane 583, Ruiguang Road, 6th Floor -3, Neihu District, Taipei, TWN, 11492
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score

Get the complete analysis for TPE:6657

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.30
Price
NT$51.42
GF Value